IMV Inc. IMV
Day range unavailable
52-week range unavailable
- Market cap
- 9.81M
- Revenue (ttm)
- 329.00K
- Shares out
- 11.71M
- Forward P/E
- -0.39
- Beta
- 1.52
- Analysts
- Buy
- Price target
- 38.33 (+4560.2%)
- Earnings date
- May 12, 2023
Key statistics
- Enterprise value
- 8.73M
- PEG ratio
- 0.00
- Price / sales
- 29.81
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 75.00%
- Free cash flow
- -21.51M
- Total cash
- 21.22M
- Total debt
- 28.90M
- Return on equity
- -508.58%
- Short % of float
- 2.66%
- 50-day average
- 0.550646
- 200-day average
- 2.73
Analyst view
Consensus: buy
- Target (low)
- 5.00
- Target (mean)
- 38.33
- Target (high)
- 60.00
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
May 12, 2023
Expected May 12, 2023. Consensus EPS estimate -1.03.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 12, 2023 | Mar 1, 2023 | -1.07 | — | — | — |
| Mar 16, 2023 | Dec 1, 2022 | -0.92 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -1.40 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -1.30 | — | — | — |
| May 13, 2022 | Mar 1, 2022 | -1.50 | — | — | — |
| Mar 17, 2022 | Dec 1, 2021 | -1.10 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 21, 2022 | HC Wainwright & Co. | main | — | Buy |
| Sep 22, 2021 | Cantor Fitzgerald | init | — | Overweight |
| May 18, 2020 | Wells Fargo | up | Equal-Weight | Overweight |
| May 15, 2020 | H.C. Wainwright | main | — | Buy |
| Apr 1, 2020 | B. Riley FBR | down | Buy | Neutral |
| Feb 28, 2020 | B. Riley FBR | reit | — | Buy |
About IMV Inc.
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- imv-inc.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on IMV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Davison (Brittany) | Senior Officer of Issuer | Opening Balance-Initial SEDI Report | Mar 31, 2022 | 15,205 |
| Maleki (Vareki Saman) | Director of Issuer | Opening Balance-Initial SEDI Report | Sep 14, 2022 | 4,365 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 7.47% | 875,000 | 719.69K | Dec 30, 2022 |
| Ruffer LLP | 2.75% | 321,952 | 264.81K | Mar 30, 2023 |
| Jane Street Group, LLC | 0.75% | 87,766 | 72.19K | Dec 30, 2022 |
| National Bank of Canada/FI | 0.46% | 53,857 | 44.30K | Mar 30, 2023 |
| LexAurum Advisors, LLC | 0.44% | 51,095 | 42.02K | Mar 30, 2023 |
| Wells Fargo & Company | 0.40% | 47,175 | 38.80K | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.04% | 4,882 | 4.01K | Feb 27, 2023 |